Biobetters Market Size, Share, Industry, Forecast and outlook (2023-2030)

Biobetters Market is expected to grow at a High CAGR of 8.5% during the forecasting period 2023-2030.

Biobetters are improved versions of existing biological drugs, offering advantages like greater efficacy, fewer side effects, and longer half-life. This growing market is driven by their potential to enhance patient outcomes and reduce healthcare costs.

The rising competition from biosimilars, which are cheaper copies of biologics, poses a challenge to the biobetters market growth. Additionally, the complex and expensive development process of biobetters can be a hurdle for smaller players.

Key players are Amgen Inc., Merck KGaA., Mabpharm Limited, F. Hoffmann-La Roche Ltd, GlaxoSmithKline plc, Celltrion Healthcare, Novo Nordisk A/S, Biogen, Aequilibrium Pharma, Pfizer and others.